# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001193125-23-192735
Filing Date
2023-07-25
Accepted
2023-07-25 07:05:31
Documents
46
Period of Report
2023-07-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | d530062d8k.htm iXBRL | 8-K | 29605
2 | EX-99.1 | d530062dex991.htm | EX-99.1 | 44133
3 | EX-99.2 | d530062dex992.htm | EX-99.2 | 30578
7 | GRAPHIC | g530062ex99_2s10g1.jpg | GRAPHIC | 77769
8 | GRAPHIC | g530062ex99_2s11g1.jpg | GRAPHIC | 86343
9 | GRAPHIC | g530062ex99_2s12g1.jpg | GRAPHIC | 96345
10 | GRAPHIC | g530062ex99_2s13g1.jpg | GRAPHIC | 124724
11 | GRAPHIC | g530062ex99_2s14g1.jpg | GRAPHIC | 83263
12 | GRAPHIC | g530062ex99_2s15g1.jpg | GRAPHIC | 65166
13 | GRAPHIC | g530062ex99_2s16g1.jpg | GRAPHIC | 84690
14 | GRAPHIC | g530062ex99_2s17g1.jpg | GRAPHIC | 71984
15 | GRAPHIC | g530062ex99_2s18g1.jpg | GRAPHIC | 64680
16 | GRAPHIC | g530062ex99_2s19g1.jpg | GRAPHIC | 51337
17 | GRAPHIC | g530062ex99_2s1g1.jpg | GRAPHIC | 72625
18 | GRAPHIC | g530062ex99_2s20g1.jpg | GRAPHIC | 87964
19 | GRAPHIC | g530062ex99_2s21g1.jpg | GRAPHIC | 118712
20 | GRAPHIC | g530062ex99_2s22g1.jpg | GRAPHIC | 138366
21 | GRAPHIC | g530062ex99_2s23g1.jpg | GRAPHIC | 76940
22 | GRAPHIC | g530062ex99_2s24g1.jpg | GRAPHIC | 89346
23 | GRAPHIC | g530062ex99_2s25g1.jpg | GRAPHIC | 85151
24 | GRAPHIC | g530062ex99_2s26g1.jpg | GRAPHIC | 89492
25 | GRAPHIC | g530062ex99_2s27g1.jpg | GRAPHIC | 132592
26 | GRAPHIC | g530062ex99_2s28g1.jpg | GRAPHIC | 98566
27 | GRAPHIC | g530062ex99_2s29g1.jpg | GRAPHIC | 60425
28 | GRAPHIC | g530062ex99_2s2g1.jpg | GRAPHIC | 67432
29 | GRAPHIC | g530062ex99_2s30g1.jpg | GRAPHIC | 79107
30 | GRAPHIC | g530062ex99_2s31g1.jpg | GRAPHIC | 52238
31 | GRAPHIC | g530062ex99_2s32g1.jpg | GRAPHIC | 62905
32 | GRAPHIC | g530062ex99_2s3g1.jpg | GRAPHIC | 192939
33 | GRAPHIC | g530062ex99_2s4g1.jpg | GRAPHIC | 59975
34 | GRAPHIC | g530062ex99_2s5g1.jpg | GRAPHIC | 99157
35 | GRAPHIC | g530062ex99_2s6g1.jpg | GRAPHIC | 102802
36 | GRAPHIC | g530062ex99_2s7g1.jpg | GRAPHIC | 81279
37 | GRAPHIC | g530062ex99_2s8g1.jpg | GRAPHIC | 122204
38 | GRAPHIC | g530062ex99_2s9g1.jpg | GRAPHIC | 66930
| Complete submission text file | 0001193125-23-192735.txt |  | 4170669

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA | stok-20230725.xsd | EX-101.SCH | 2880
5 | XBRL TAXONOMY EXTENSION LABEL LINKBASE | stok-20230725_lab.xml | EX-101.LAB | 17978
6 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | stok-20230725_pre.xml | EX-101.PRE | 11278
40 | EXTRACTED XBRL INSTANCE DOCUMENT | d530062d8k_htm.xml | XML | 3341

Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 231106439
SIC: 2834 Pharmaceutical Preparations